ストックスクリーナーアプリを入手
0.1864
6.76%
0.0118
アフターアワーズ：
.18
-0.0064
-3.43%
Vivos Therapeutics Inc (VVOS) 最新ニュース
Vivos Therapeutics Inc (NASDAQ: VVOS) Share Price, VVOS Stock News, VVOS Share Price & Updates - Kalkine
Vivos Therapeutics (VVOS) investor lists 122,963 shares, under 5% - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference - tradingview.com
Vivos Therapeutics Surges as Investors Weigh Nevada Growth Updates and Florida Expansion Plan - Moomoo
Vivos Therapeutics partners with Florida cardiology group for sleep center - Investing.com
Vivos Therapeutics partners with Florida cardiology group for sleep center By Investing.com - Investing.com UK
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center - marketscreener.com
Vivos Therapeutics Inc. (VVOS) Peer Comparison – Compare with Others - valueresearchonline.com
Vivos Therapeutics (VVOS) grants 250K shares, 150K options - Stock Titan
Vivos Therapeutics reports 212% rise in Nevada patient referrals By Investing.com - Investing.com Canada
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers - Barchart.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Vivos Therapeutics Inc (VVOS) Stock News Today - TradingKey
Vivos Therapeutics opens Henderson facility with $10M capacity - Investing.com
Vivos Therapeutics Opens Nevada Sleep Treatment Center - marketscreener.com
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment - The Manila Times
Vivos Therapeutics opens Henderson facility with $10M capacity By Investing.com - Investing.com Canada
Vivos Therapeutics Opens New Henderson Sleep Center, Expects Capacity to More Than Double to Over $10 Million Annually - Moomoo
Vivos expects its Nevada sleep center to more than double annual capacity to $10M+ - Stock Titan
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... By GuruFocus - Investing.com Canada
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance
Vivos Therapeutics stock falls 6% on second quarter revenue miss By Investing.com - Investing.com Canada
Vivos Therapeutics stock falls 6% on second quarter revenue miss - Investing.com
Conferencia de resultados del 2T de 2026 de Vivos Therapeutics (VVOS): los ingresos suben un 35%, persisten los riesgos de liquidez - TradingKey
Vivos Therapeutics (VVOS) Q2 2026 Earnings Call: Umsatz steigt um 35 %, Liquiditätsrisiken bestehen weiterhin - TradingKey
Vivos Therapeutics partners with SPCVA to form AIM Florida - scanx.trade
Vivos Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Vivos Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Vivos gets Washington license to manufacture IsoPet - scanx.trade
Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Vivos Therapeutics posts strong Q2 2026 revenue growth - Investing.com Canada
Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com - Investing.com Canada
Vivos Therapeutics Q2 revenue up 35%; targets positive cash flow by late 2026 - scanx.trade
Vivos Therapeutics reports 35% revenue increase in Q2 2026 - Investing.com
Vivos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vivos Therapeutics Q2 revenue rises 35% on service growth - TradingView
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results - Quiver Quantitative
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update - Yahoo Finance
Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary - TradingView
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS) - Stock Titan
Vivos Therapeutics schedules Q2 2026 results, conference call - scanx.trade
Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn - Stock Titan
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call - marketscreener.com
Vivos Therapeutics (VVOS) Edges Higher as Penny Stock Holds Support Near $0.29High Reward Trades - Vinanet
Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices - TipRanks
Vivos Oral Appliance Shows Improvement in Insomnia Severity - Sleep Review
Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS) - Stock Titan
Vivos partners with Greenway Health to deploy AI platform - Investing.com
Vivos partners with Greenway Health to deploy AI platform By Investing.com - Investing.com Nigeria
0.86%
0.13%
大文字化:
|
ボリューム (24 時間):